Article,

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy

, , , , , , , , , , and .
Journal of Cancer Research and Clinical Oncology, (Feb 4, 2021)
DOI: 10.1007/s00432-021-03511-y

Abstract

Classification and treatment of WHO grade II/III gliomas have dramatically changed. Implementing molecular markers into the WHO classification raised discussions about the significance of grading and clinical trials showed overall survival (OS) benefits for combined radiochemotherapy. As molecularly stratified treatment data outside clinical trials are scarce, we conducted this retrospective study.

Tags

Users

  • @marcsaric

Comments and Reviews